Veterinary Animal Healthcare Market Size and Share

Veterinary Animal Healthcare Market (2026 - 2031)

Veterinary Animal Healthcare Market Analysis by 麻豆视频

The Veterinary Animal Healthcare Market size is projected to expand from USD 62.28 billion in 2025 and USD 66.48 billion in 2026 to USD 92.34 billion by 2031, registering a CAGR of 6.79% between 2026 to 2031.

Growth is underpinned by the convergence of protein-supply security, companion-animal welfare, and rapid diagnostic innovation. Combination vaccines and monoclonal antibodies now reach commercial launch in 24鈥�30 months, compressing historical timelines and enlarging addressable volumes for biologics. Early disease detection is gaining parity with therapeutics in capital budgets, as benchtop PCR systems and AI-augmented imaging shorten turnaround times from days to minutes. Tightening antimicrobial-stewardship rules are accelerating substitution toward narrow-spectrum drugs, probiotic feed additives, and autogenous vaccines. Meanwhile, vertical integration among corporate practice groups raises equipment-integration requirements that favor suppliers offering plug-and-play software and remote-support ecosystems.

Key Report Takeaways

  • By product, therapeutics commanded 62.4% of 2025 revenue, while diagnostics are advancing at a 7.86% CAGR to 2031, the fastest within the Veterinary Animal Healthcare Market.
  • By animal type, dogs and cats led with 55.1% of 2025 revenue; poultry is expanding at a 7.12% CAGR through 2031. 
  • By route of administration, parenteral delivery held 52.3% of 2025 revenue; oral formulations are projected to grow at 7.33% CAGR to 2031. 
  • By end user, hospitals and clinics contributed 57.7% of 2025 revenue, yet point-of-care settings are accelerating at an 8.32% CAGR through 2031. 
  • By geography, North America represented 45.3% of the Veterinary Animal Healthcare Market share in 2025, while Asia-Pacific is forecast to post the highest regional CAGR at 8.11% to 2031.

Note: Market size and forecast figures in this report are generated using 麻豆视频鈥檚 proprietary estimation framework, updated with the latest available data and insights as of 2026.

Segment Analysis

By Product: Diagnostics Outpace Therapeutics in Innovation Velocity

Therapeutics accounted for 62.4% of 2025 revenue within the Veterinary Animal Healthcare Market, anchored by combination vaccines and anti-infectives. Diagnostics are forecast to grow at 7.86% annually, supported by point-of-care immunoassays and AI-enabled imaging. Vaccines dominate therapeutic volume, with multivalent canine and bovine formulations displacing monovalent products. Pricing pressure on parasiticides arises as isoxazoline generics arrive, yet new chewable endectocides that cover flea, tick, and heartworm in one dose gain traction.

Molecular diagnostics expand as PCR unit prices fall below USD 15,000, opening mid-tier clinic adoption. Portable ultrasound and digital radiography penetrate equine and large-animal field work where ruggedness and mobility are essential. Clinical-chemistry analyzers bundled with hematology modules become standard in critical-care rooms, reducing reliance on external labs. Feed additives based on phytogenics deliver 4鈥�7% feed-conversion gains relative to antibiotics. Anti-infective portfolios increasingly emphasize narrow-spectrum cephalosporins that meet stewardship criteria.

Veterinary Animal Healthcare Market: Market Share by Product

By Animal Type: Poultry Biosecurity Drives Fastest Expansion

Dogs and cats commanded 55.1% of 2025 revenue, reflecting high spend on preventive dentistry, orthopedic repair, and oncology. Poultry is the fastest-growing segment, advancing at 7.12% CAGR to 2031 as Asia-Pacific integrators lift biosecurity spend and deploy onsite influenza antigen tests. The Veterinary Animal Healthcare Market size for poultry is projected to expand at USD-denominated mid-single-digit billions by 2031, reflecting continuous integration investments.

Equine care remains niche, driven by performance-medicine spending in North America and Europe. Dairy operations intensify mastitis-prevention and reproductive-efficiency programs, while beef herds shrink amid drought and plant-protein consumption trends. Swine herds in China and Vietnam rebuild after ASF, driving sales of biosecure infrastructure. Aquaculture vaccines reduce antibiotic use 30% since 2023, boosting health budgets in Norwegian salmon and Southeast Asian shrimp farming. The Veterinary Animal Healthcare Market share for exotic and zoo animals remains under 2%, concentrated in accredited institutions.

By Route of Administration: Oral Gains on Palatability Breakthroughs

Parenteral formats captured 52.3% of 2025 revenue in the Veterinary Animal Healthcare Market, led by vaccines and long-acting injectables. Oral formulations are forecast to expand at a 7.33% CAGR as flavor-masking and chewable matrices increase owner compliance. Lipid-based carriers improve bioavailability for hydrophobic actives and enable once-monthly chewable antiparasitics that match injectable duration.

Topicals face competition from systemic options but retain popularity among owners wary of needles. Long-acting injectables such as moxidectin extend dosing intervals to quarterly, enhancing livestock compliance. 

Intramammary and intra-articular routes serve specialized needs like mastitis and equine joint disease. Veterinary Animal Healthcare Market size growth for oral formats is reinforced by livestock drenches and in-feed nutraceuticals that avoid antimicrobial classifications.

Veterinary Animal Healthcare Market: Market Share by Route of Adminstration
Veterinary Animal Healthcare Market: Market Share by Route of Adminstration

By End User: Point-of-Care Settings Reshape Diagnostic Workflows

Hospitals and clinics generated 57.7% of 2025 revenue, yet in-house and point-of-care venues are growing fastest at 8.32% CAGR. Analyzers deliver complete blood counts in under 15 minutes, negating courier lead times and propelling Veterinary Animal Healthcare Market penetration among mobile practices. Reference labs maintain leadership in histopathology and genomic services, though turnaround gaps narrow.

Corporate consolidation standardizes procurement, privileging suppliers with integrated instrumentation and centralized support. On-farm diagnostics for pregnancy and mastitis underpin livestock decision-making. Mobile clinics equipped with handheld ultrasound and battery-powered hematology units extend veterinary reach into underserved territories. Telemedicine further blends end-user boundaries, routing triage between home care and referral centers, thereby expanding the Veterinary Animal Healthcare Market footprint.  

Geography Analysis

North America accounted for 45.3% of 2025 revenue due to high per-pet spend and consolidated practice networks. Asia-Pacific is projected to grow at 8.11% CAGR, adding USD-denominated double-digit billions to the Veterinary Animal Healthcare Market size by 2031. China鈥檚 pet population exceeded 120 million dogs and cats, fueling multispecialty clinic growth. India鈥檚 dairy sector elevates veterinary input intensity, though rural coverage gaps persist, creating room for mobile and tele-health service expansion.

Europe benefits from stringent welfare rules that mandate veterinary oversight across production systems, yet stagnant companion-animal numbers temper revenue growth. The EU Farm-to-Fork strategy鈥檚 50% antimicrobial-reduction target accelerates vaccine and probiotic adoption. Middle East and Africa present bifurcated demand: Gulf states invest in camel and equine centers, while sub-Saharan regions focus on cold-chain expansions for livestock vaccines.

South America鈥檚 export-oriented poultry and beef sectors invest in traceability and surveillance to satisfy import partners, driving Veterinary Animal Healthcare Market adoption of rapid PCR and blockchain certification. Brazil鈥檚 USD 240 million 2025 traceability outlay underscores commitment to disease-free status. Argentina and Colombia replicate Brazil鈥檚 hatchery-based PCR programs. Across regions, tele-enabled clinics and thermostable biologics emerge as common denominators of future growth

Veterinary Animal Healthcare Market CAGR (%), Growth Rate by Region

Regulatory Landscape

Veterinary animal healthcare regulation is organized through structured pathways across major markets. In the European Union, Regulation (EU) 2019/6 governs authorization, manufacturing, import/export, and pharmacovigilance for veterinary medicinal products, with EMA/CVMP oversight and GMP requirements shaping dossiers and post-market obligations. In the United States, veterinary drugs move through FDA Center for Veterinary Medicine processes, including New Animal Drug Applications, under the FDCA, while veterinary vaccines and other biologics are regulated by USDA APHIS. This split framework affects development sequencing and launch strategy.

Recent regulatory and compliance updates also add detail and time costs for labeling, submissions, and disease-control use cases. The EU introduced Commission Delegated Regulation (EU) 2026/1073 (March 6, 2026), updating rules for using veterinary medicinal products to prevent or control category A and B diseases. EMA also updated its procedural guidance on mock-ups for veterinary medicines (March 5, 2026), alongside recommended submission-date guidance for 2024-2026. Trade compliance adds another constraint, since US import duty exposure varies by classification and origin, including potential additional tariffs on certain origins and active ingredients, which increases the need for supply-chain planning and regional manufacturing footprints for global brands.

Competitive Landscape

The Veterinary Animal Healthcare Market is moderately consolidated; the top five players capture about majority of global revenue. Zoetis, Boehringer Ingelheim, and Merck Animal Health leverage integrated R&D pipelines to launch combination vaccines that reduce handling steps and improve compliance. Diagnostic specialists such as IDEXX and Heska embed AI algorithms that auto-interpret hematology and imaging results, cutting turnaround times by one-third. White-space opportunities include thermostable livestock vaccines, cloud-native telemedicine platforms, and aquaculture biologics with proprietary adjuvants.

Patent filings for machine-learning image analysis rose significantly in 2025, signaling intellectual-property stakes as point-of-care devices commoditize. Regulatory costs rise under FDA Guidance 263 and EMA pharmacovigilance extensions, pressuring smaller firms toward licensing or acquisition. Geographic portfolios diverge: companion-animal leaders prioritize China鈥檚 urban segments, whereas livestock-focused firms invest in Brazil, Vietnam, and parts of Africa where protein demand outpaces infrastructure. Practice-group consolidation raises integration barriers, cementing incumbency for vendors with seamless EHR connectivity and automated inventory replenishment. 

Veterinary Animal Healthcare Industry Leaders

  1. Zoetis Inc.

  2. Boehringer Ingelheim International GmbH

  3. Elanco Animal Health

  4. Merck & Co., Inc.

  5. IDEXX Laboratories Inc

  6. *Disclaimer: Major Players sorted in no particular order
Veterinary Healthcare Market Concentration

Market Opportunities and Future Outlook

White-space growth is most visible where stewardship and welfare requirements shift budgets away from broad antibiotic use and toward vaccines, diagnostics, and data-enabled prevention. Regulation-driven antimicrobial reduction programs, including EU Farm-to-Fork execution at the member-state level and tighter stewardship in North America, support wider uptake of rapid susceptibility testing, narrow-spectrum therapy selection, autogenous vaccines, and non-antibiotic feed additives. This environment also favors suppliers that can support routine diagnostic capture and compliance documentation around disease control.

Manufacturing and capability investments provide clearer signals on where suppliers are directing capital, particularly for biologics and vaccine capacity. Merck Animal Health announced an USD 895 million investment (May 2025) to expand manufacturing and R&D facilities in De Soto, Kansas, focused on vaccines and biologics. Ceva disclosed investment in a new 7,000 square meter vaccine manufacturing plant (November 2024) to expand global production. In Europe, Dopharma and Ripac-Labor marked a topping-out for a new autogenous vaccine production facility in Potsdam, Germany (April 2026), underscoring continued build-out around customized livestock immunization within regulated frameworks and faster outbreak response.

Recent Industry Developments

  • July 2026: Zoetis announced an agreement to acquire VitalRADS, adding diagnostic capabilities that broaden its presence in imaging-led workflows. The transaction supports tighter integration between practice decision-making and companion-animal care pathways, aligning with the market shift toward faster diagnosis and software-enabled follow-up.
  • March 2026: Zoetis announced an agreement to acquire Neogen Corporation's animal genomics business for USD 160 million to advance Precision Animal Health. The acquisition expands access to genomics data assets and tools that can be linked with diagnostics and herd management, reinforcing data-driven preventive and productivity programs in livestock systems.
  • October 2024: Boehringer Ingelheim opened a USD 66.1 million expansion of its Athens, Georgia, research and development facility, adding both laboratory and administrative space. The expanded footprint strengthens development capacity for new veterinary medicines and supports faster iteration across pipelines as regulatory and pharmacovigilance requirements continue to intensify.

Table of Contents for Veterinary Animal Healthcare Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Protein-Rich Animal Products
    • 4.2.2 Increasing Pet Humanization and Healthcare Spending
    • 4.2.3 Expanding Livestock Production in Emerging Economies
    • 4.2.4 Digital Transformation of Veterinary Practices
    • 4.2.5 Tele-Medicine-Based Herd-Health Management Growth
    • 4.2.6 AI-Enabled Early Disease-Detection Platforms
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Compliance & Approval Timelines
    • 4.3.2 Antimicrobial-Resistance Stewardship Restrictions
    • 4.3.3 Cold-Chain Gaps for Critical Biologics
    • 4.3.4 Alternative-Protein Diets Curb Livestock Numbers
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter鈥檚 Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product
    • 5.1.1 Therapeutics
    • 5.1.1.1 Vaccines
    • 5.1.1.2 Parasiticides
    • 5.1.1.3 Anti-Infectives
    • 5.1.1.4 Medical Feed Additives
    • 5.1.1.5 Other Therapeutics
    • 5.1.2 Diagnostics
    • 5.1.2.1 Immunodiagnostic Tests
    • 5.1.2.2 Molecular Diagnostics
    • 5.1.2.3 Diagnostic Imaging
    • 5.1.2.4 Clinical Chemistry
    • 5.1.2.5 Other Diagnostics
  • 5.2 By Animal Type
    • 5.2.1 Dogs & Cats
    • 5.2.2 Horses
    • 5.2.3 Ruminants
    • 5.2.4 Swine
    • 5.2.5 Poultry
    • 5.2.6 Other Animal Types
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Parenteral
    • 5.3.3 Topical
    • 5.3.4 Other Routes
  • 5.4 By End User
    • 5.4.1 Veterinary Hospitals & Clinics
    • 5.4.2 Reference Laboratories
    • 5.4.3 Point-of-Care / In-House Settings
    • 5.4.4 Academic & Research Institutes
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
    • 6.3.1 Bimeda
    • 6.3.2 Boehringer Ingelheim
    • 6.3.3 Ceva Sant茅 Animale
    • 6.3.4 Covetrus
    • 6.3.5 Dechra Pharmaceuticals
    • 6.3.6 Elanco
    • 6.3.7 Heska Corporation
    • 6.3.8 IDEXX Laboratories
    • 6.3.9 ImmuCell
    • 6.3.10 INDICAL Bioscience
    • 6.3.11 Innovative Diagnostics (IDVet)
    • 6.3.12 Merck Animal Health
    • 6.3.13 Neogen Corporation
    • 6.3.14 Norbrook
    • 6.3.15 PetIQ
    • 6.3.16 Phibro Animal Health
    • 6.3.17 Randox Laboratories
    • 6.3.18 Thermo Fisher Scientific
    • 6.3.19 Vetoquinol
    • 6.3.20 Virbac
    • 6.3.21 Zoetis
    • 6.3.22 Zomedica

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment

Research Methodology Framework and Report Scope

Market Definition and Coverage

This market covers spending on veterinary animal healthcare products and solutions used to prevent, diagnose, and treat health conditions in animals, across companion and production animals, and across all major regions.

Scope exclusions: Human healthcare, on-farm nutrition not sold as medicated feed additives, and general pet supplies (such as grooming and accessories) are excluded from the market totals.

Segmentation Overview

  • By Product
    • Therapeutics
      • Vaccines
      • Parasiticides
      • Anti-Infectives
      • Medical Feed Additives
      • Other Therapeutics
    • Diagnostics
      • Immunodiagnostic Tests
      • Molecular Diagnostics
      • Diagnostic Imaging
      • Clinical Chemistry
      • Other Diagnostics
  • By Animal Type
    • Dogs & Cats
    • Horses
    • Ruminants
    • Swine
    • Poultry
    • Other Animal Types
  • By Route of Administration
    • Oral
    • Parenteral
    • Topical
    • Other Routes
  • By End User
    • Veterinary Hospitals & Clinics
    • Reference Laboratories
    • Point-of-Care / In-House Settings
    • Academic & Research Institutes
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Data Sources, Market Sizing, and Validation

Desk Research

Desk research starts with compiling a fact base for animal populations, disease burden, and regulated product categories, so the model applies consistent in-scope definitions. We use public sources such as the World Organisation for Animal Health (WOAH) for animal health event context, FAOSTAT for livestock population and production background, and the World Bank for macro indicators that influence veterinary spending patterns.

Pricing and volume direction are then checked using sources such as USDA for animal health and livestock statistics, the European Medicines Agency public materials for veterinary medicine context, and peer reviewed veterinary science journals for therapy and testing trends. We also review company filings and investor presentations to understand business mix, plus reputable press and association websites for product launches and policy updates. When needed, we reference paid database subscriptions for company financials and intelligence, patent databases, and shipment level import and export trade data to validate product flow and adoption timing. These sources are not exhaustive, and we also used other public references for data collection, validation, and clarification.

Primary Interviews and Surveys

Primary interviews focus on confirming what gets counted as veterinary therapeutics and diagnostics revenue, and how demand shifts by animal type and channel. We speak with product manufacturers, distributors, veterinary hospital and clinic operators, reference lab leaders, and practicing veterinarians across APAC, EMEA, and the Americas, so assumptions on volumes, pricing, and mix changes can be stress tested against on-the-ground experience.

Distribution of primary research fieldwork respondents

Company typeRespondent positionRegion
Top tier: 36% CXOs: 15%APAC: 46%
Mid tier: 44% Functional/Unit leaders: 41%EMEA: 33%
Smaller Players: 20% Managers: 44%Americas: 21%

Market-Sizing & Forecasting

Sizing is built using a top-down approach where animal population by species and geography is converted into an addressable care and treatment pool, and then scaled using category level usage and pricing checks. For veterinary animal healthcare, the model is anchored on indicators such as companion animal ownership trends, livestock headcount and production intensity, incidence of key infectious and parasitic conditions, veterinary visit and testing frequency, and the mix shift between therapeutics and diagnostics.

Those totals are then corroborated using selective bottom-up approximations, including sampled average selling price times estimated volumes for common therapy classes, plus channel checks across clinics, hospitals, and reference labs. Where local splits are missing, gaps are handled using proxy ratios from similar countries with comparable animal demographics and care access, then adjusted after expert feedback. Forecasts use scenario analysis supported by simple multivariate regression on the most explanatory drivers (animal population, veterinary access, and pricing progression), and assumptions are revisited when primary inputs indicate a change in adoption pace.

Data Validation & Update Cycle

Model outputs are cross-checked against independent signals such as reported veterinary product revenue trends, diagnostics testing expansion cues, and major regulatory actions that can shift availability. Variances are reviewed in multiple steps, with a second analyst checking formulas, units, and currency conversions before sign-off.

If a key input changes sharply, such as a disease outbreak, a large pricing reset, or a policy change affecting veterinary medicines, we re-contact selected experts to confirm the impact and update assumptions. Reports are refreshed annually, and interim updates are made when material events affect market direction. Before delivery, a final pass is completed so clients receive the most current view supported by the latest checks.

麻豆视频's Global Veterinary Animal Healthcare Market Market Size Compared Against Other Published Estimates

Published market numbers for veterinary animal healthcare often differ because the same terms can hide different inclusions, such as whether telehealth software, livestock monitoring, and non-veterinary services are counted, and how medicated feed additives are treated. Differences also show up when firms choose different base years, apply different currency timing, or use aggressive growth assumptions for new diagnostics formats.

Some external estimates fold broader animal health adjacencies into the total, which increases the headline value. In 麻豆视频, the count is limited to veterinary therapeutics (including vaccines, parasiticides, anti-infectives, and medical feed additives) plus veterinary diagnostics, and it is then checked by animal type, end user channel, and region before the final number is published.

Benchmark comparison

SourceMarket SizeGaps in Research Methodology
麻豆视频 USD 66.48 B (2026)
Global Consultancy A USD 78.27 B (2026)Uses a broader animal health scope that can include adjacent digital tools and monitoring solutions alongside core products, and this can lift totals when bundled under one spend bucket.
Industry Publisher B USD 75.30 B (2026)Often treats the market as a wider animal health spend pool with added service and channel components, and may apply faster pricing and adoption ramps that are not always validated by clinic and lab level checks.

The spread across the three values is mainly explained by what is counted as in-scope and how quickly pricing and adoption are allowed to change in the forecast. By tying the estimate to clear product categories, animal cohorts, and practical demand indicators, our approach stays easier to trace and repeat from one update cycle to the next.

Key Questions Answered in the Report

What is the current size and growth outlook for global veterinary healthcare?

Revenues stand at USD 66.48 billion in 2026 and are forecast to reach USD 92.34 billion by 2031, reflecting a 6.79% CAGR.

Which product line is showing the fastest expansion?

Diagnostics leads growth at a 7.86% CAGR through 2031, driven by molecular point-of-care platforms and rapid in-clinic testing.

How does rising pet humanization affect spending?

Owners treat pets as family members, lifting average U.S. veterinary bills to USD 1,480 per household in 2024 and boosting demand for premium therapies and insurance uptake.

Why is poultry health spending accelerating?

Intensive production and biosecurity rules push poultry to a 7.12% CAGR, with mandatory vaccines and rapid pathogen screening becoming routine.

What impact do point-of-care diagnostics have on veterinary clinics?

In-house analyzers deliver results within minutes, raise case acceptance, and are propelling the fastest end-user growth segment at a 7.28% CAGR.

What key obstacles limit broader product adoption?

Lengthy regulatory approvals add up to two years per novel therapy, while equipment costs above USD 100,000 restrict access for rural and emerging-market clinics.

Page last updated on:

Veterinary Animal Healthcare Market Report Snapshots